Active, not recruitingPhase 2NCT06928376

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

Studying Acute promyelocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese PLA General Hospital
Intervention
Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor(drug)
Enrollment
160 target
Eligibility
14-75 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

First Affiliated Hospital of Harbin Medical University · Yantai Yuhuangding Hospital · Chinese People's Liberation Army Air Force General Hospital · The General Hospital of Western Theater Command · 940 Hospital of the People's Liberation Army Joint Logistic Support Force · The 960th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army · the First People's Hospital of Jining

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06928376 on ClinicalTrials.gov

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute promyelocytic leukemia →

← Back to all trials